| 27.12 -0.62 (-2.24%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.85 | 1-year : | 40.7 |
| Resists | First : | 29.84 | Second : | 34.85 |
| Pivot price | 26.96  |
|||
| Supports | First : | 24.37 | Second : | 20.99 |
| MAs | MA(5) : | 27.96 |
MA(20) : | 26.62 |
| MA(100) : | 23.85 |
MA(250) : | 22.95 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 57.2 |
D(3) : | 73.4 |
| RSI | RSI(14): 58.5 |
|||
| 52-week | High : | 31.77 | Low : | 13.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARQT ] has closed below upper band by 45.6%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.29 - 27.44 | 27.44 - 27.56 |
| Low: | 25.76 - 25.95 | 25.95 - 26.1 |
| Close: | 26.84 - 27.12 | 27.12 - 27.36 |
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Wed, 08 Jul 2026
Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT) - Seeking Alpha
Wed, 08 Jul 2026
Arcutis Biotherapeutics (ARQT) Receives FDA Acceptance for Zoryve Cream - GuruFocus
Sun, 05 Jul 2026
Price to earnings forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Thu, 02 Jul 2026
Arcutis lures 9 new hires with 61,000 stock awards - Stock Titan
Mon, 29 Jun 2026
Arcutis Biotherapeutics (ARQT) Secures FDA Approval for ZORYVE C - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 125 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 110 (%) |
| Shares Short | 14,020 (K) |
| Shares Short P.Month | 16,230 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.51 |
| Profit Margin | -0.6 % |
| Operating Margin | -8.7 % |
| Return on Assets (ttm) | 0.5 % |
| Return on Equity (ttm) | -1.5 % |
| Qtrly Rev. Growth | 60 % |
| Gross Profit (p.s.) | 3.02 |
| Sales Per Share | 3.32 |
| EBITDA (p.s.) | 0.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 27 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -1356.01 |
| PEG Ratio | 0 |
| Price to Book value | 17.84 |
| Price to Sales | 8.16 |
| Price to Cash Flow | 125.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|